8114 Journal of Medicinal Chemistry, 2010, Vol. 53, No. 22
Shook et al.
dopamine receptors in rat striatum. Mol. Brain Res. 1992, 14,
186–195.
(3) Schiffmann, S. N.; Lipert, F.; Vassart, G.; Vanderhaeghen, J. J.
Distribution of adenosine A2receptor mRNA in the human brain.
Neurosci. Lett. 1991, 130, 177–181.
A
2A receptor blockade in experimental models of Parkinson's disease.
J. Neurochem. 2002, 80, 262–270.
(15) (a) Kanda, T.; Jackson, M. J.; Smith, L. A.; Pearce, R. K. B.;
Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Adenosine A2A
antagonist: a novel antiparkinsonian agent that does not provoke
dyskinesia in parkinsonian monkeys. Ann. Neurol. 1998, 43, 507–
513. (b) Koga, K.; Kurokawa, M.; Ochi, M.; Nakamura, J.; Kuwana, Y.
Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate
rotation induced by dopaminergic drugs in hemi-Parkinsonian rats. Eur.
J. Pharmacol. 2000, 408, 249–255.
(16) (a) Kanda, T.; Jackson, M. J.; Smith, L. A.; Pearce, R. K.;
Nakamura, J.; Kase, H.; Kuwana, Y.; Jenner, P. Combined use
of the adenosine A2A antagonist KW-6002 with L-DOPA or with
selective D1 or D2 dopamine agonists increases antiparkinsonian
activity but not dyskinesia in MPTP-treated monkeys. Exp. Neurol.
2000, 162, 321–327. (b) Hauser, R. A.; Hubble, J. P.; Truong, D. D.
Randomized trial of adenosine A2A receptor antagonist istradefylline in
advanced PD. Neurology 2003, 61, 297–303. (c) Bara-Jimenez, W.;
Sherzai, A.; Dimitrova, T.; Favit, A.; Bibbiani, F.; Gillespie, M.; Morris,
M. J.; Mouradian, M. M.; Chase, T. N. Adenosine A2A receptor
antagonist treatment of Parkinson's disease. Neurology 2003, 61,
293–296.
(4) Olanow, C. W. MAO-B inhibitors in Parkinson’s disease. Adv.
Neurol. 1993, 60, 666–671.
(5) (a) Gordin, A.; Brooks, D. J. Clinical pharmacology and thera-
peutic use of COMT inhibition in Parkinson’s disease. J. Neurol.
2007, 254, IV/37–IV/48. (b) Olanow, C. W.; Stocchi, F. COMT
inhibitors in Parkinson's disease. Can they prevent and/or reverse
levodopa-induced motor complications? Neurology 2004, 62, S72–
S81.
(6) (a) Antonini, A.; Clilia, R. Behavioural adverse effects of dopami-
nergic treatments in Parkinson’s disease: incidence, neurobiologi-
cal basis, management and prevention. Drug Safety 2009, 32, 475–
488. (b) Hansard, M. J.; Smith, L. A.; Jackson, M. J.; Cheetham, S. C.;
Jenner, P. Dopamine, but not norepinephrine or serotonin, reuptake
inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetra-
hydropyridine-treated primates. J. Pharmacol. Exp. Ther. 2002, 303,
952–958.
(7) (a) Antonini, A.; Tolosa, E.; Mizuno, Y.; Yamamoto, M.; Poewe,
W. H. A reassessment of risks and benefits of dopamine agonists in
Parkinson’s disease. Lancet Neurol. 2009, 8, 929–937. (b) Yamamoto,
M.; Schapira, A. H. V. Dopamine agonists in Parkinson's disease. Expert
Rev. Neurother. 2008, 8, 671–677.
(17) Ballarin, M.; Reiriz, J.; Ambrosio, S.; Mahy, N. Effect of locally
infused 2-cholroadenosine, an A1 receptor agonist, on spontaneous
and evoked dopamine release in rat neostriatum. Neurosci. Lett.
1995, 185, 29–32.
(18) (a) Moore, K. A.; Nicoll, R. A.; Schmitz, D. Adenosine gates
synaptic plasticity at hippocampal mossy fiber synapses. Proc. Nat.
Acad. Sci. U.S.A. 2003, 100, 14397–14402. (b) Rebola, N.; Pinheiro,
P. C.; Oliveira, C. R.; Malva, J. O.; Cunha, R. A. Subcellular localization
of adenosine A1 receptors in nerve terminal and synapses of the rat
hippocampus. Brain Res. 2003, 987, 49–58.
(19) Maemoto, T.; Miho, T.; Takuma, M.; Noriko, U.; Hideaki, M.;
Katsuya, H.; Takayuki, Y.; Kiyoharu, S.; Satoru, K.; Atsushi, A.;
Akinori, I.; Nobuya, M.; Seitaro, M. Pharmacological character-
ization of FR194921, a new potent, selective, orally active antago-
nist for central adenosine A1 receptors. J. Pharmacol. Sci. 2004, 96,
42–52.
(20) (a) Shook, B. C.; Rassnick, S.; Hall, D.; Rupert, K. C.; Heintzelman,
G. R.; Hansen, K.; Chakravarty, D.; Bullington, J. L.; Scannevin, R.;
Magliaro, B.; Westover, L.; Carroll, K.; Lampron, L.; Russell, R.;
Branum, S.; Wells, K.; Damon, S.; Youells, S.; Li, X.; Osbourne, M.;
Demarest, K.; Tang, Y.; Rhodes, K.; Jackson, P. F. Methylene amine
substituted arylindenopyrimidines as potent adenosine A2A/A1
antagonists. Bioorg. Med. Chem. Lett. 2010, 20, 2864–2867. (b) Shook,
B. C.; Rassnick, S.; Chakravarty, D.; Wallace, N.; Ault, M.; Crooke, J.;
Barbay, J. K.; Wang, A.; Leonard, K.; Powell, M. T.; Alford, V.; Hall,
D.; Rupert, K. C.; Heintzelman, G. R.; Hansen, K.; Bullington, J. L.;
Scannevin, R.; Carroll, K.; Lampron, L.; Westover, L.; Russell, R.;
Branum, S.; Wells, K.; Damon, S.; Youells, S.; Beauchamp, D.; Li, X.;
Rhodes, K.; Jackson, P. F. Optimization of arylindenopyrimidines as potent
adenosine A2A/A1 antagonists. Bioorg. Med. Chem. Lett. 2010, 20,
2868–2871.
(21) Zarrindast, M. R.; Modabber, M.; Sabetkasai, M. Influence on
different adenosine receptor subtypes on catalepsy in mice. Psy-
chopharmacology 1993, 113, 257–261.
(22) Mandhane, S. N.; Chopde, C. T.; Ghosh, A. K. Adenosine A2
receptors modulate haloperidol-induced catalepsy in rats. Eur. J.
Pharmacol. 1997, 328 (2/3), 135–141.
(23) Cooper, D. R.; Marrel, C.; van de Waterbeemd, H.; Testa, B.;
Jenner, P.; Marsden, C. D. L-Dopa esters as potential prodrugs:
behavioral activity in experimental models of Parkinson’s disease.
J. Pharm. Pharmacol. 1987, 39, 627–635.
(24) (a) Ungerstedt, U. 6-Hydroxydopamine-induced generation of
central monoamine neurons. Eur. J. Pharmacol. 1968, 5, 107–110.
(b) Ungerstedt, U.; Arbuthnott, G. W. Quantitative recording of rota-
tional behavior in rats after 6-hydroxy-dopamine lesions of the nigros-
triatal dopamine system. Brain Res. 1970, 24, 485–493. (c) Luthman,
J.; Fredriksson, A.; Sundstroem, E.; Jonsson, G.; Archer, T. Selective
lesion of central dopamine or moradenaline neuron systems in the
neonatal rat: motor behavior and monoamine alteration at adult stage.
Behav. Brain Res. 1989, 33, 267–277.
(8) (a) Neustadt, B. R.; Liu, H.; Hao, J.; Greenlee, W. J.; Stamford,
A. W.; Foster, C.; Arik, L.; Lachowicz, J.; Zhang, H.; Bertorelli, R.;
Fredduzzi, S.; Varty, G.; Cohen-Williams, M.; Ng, K. Potent
and selective adenosine A2A antagonists 1,2,4-triazolo[1,5-c]-
pyrimidines. Bioorg. Med. Chem. Lett. 2009, 19, 967–971. (b) Slee,
D. H.; Zhang, X.; Moorjani, M.; Lin, E.; Lanier, M. C.; Chen, Y.; rueter,
J. K.; Lechner, S. M.; Markison, S.; Malany, S.; Joswig, T.; Santos, M.;
Gross, R. S.; Williams, J. P.; Castro-Palomino, J. C.; Crespo, M. I.; Prat,
M.; Gual, S.; Diaz, J. L.; Wen, J.; O'Brien, Z.; Saunders, J. Identification
of novel, water soluble, 2-amino-N-pyrimin-4-ylacetamides as A2A
receptor antagonists with in vivo activity. J. Med. Chem. 2008, 51,
400–406. (c) Shao, Y.; Cole, A. G.; Brescia, M. R.; Qin, L. Y.; Duo, J.;
Stauffer, T. M.; Rokosz, L. L.; McGuinness, B. F.; Henderson, I.
Synthesis and SAR studies of trisubstituted purinones as potent and
selective adenosine A2A receptor antagonists. Bioorg. Med. Chem.
Lett. 2009, 19, 1399–1402. (d) Vu, C. B.; Peng, B.; Kumaravel, G.;
Smits, G.; Jin, X.; Phadke, D.; Engber, T.; Huang, C.; Reilly, J.; Tam, S.;
Grant, D.; Hetu, G.; Chen, L.; Zhang, J.; Petter, R. C. Piperazine
derivatives of 1,2,4-triazolo[1,5-a][1,3,5]triazine as potent and selective
adenosine A2A receptor antagonists. J. Med. Chem. 2004, 47, 4291–
4299.
(9) (a) Latini, S.; Pedata, F. Adenosine in the central nervous system:
release mechanisms and extracellular concentrations. J. Neuro-
chem. 2001, 79, 463–484. (b) Dunwiddie, T. V.; Masino, S. A. The role
and regulation of adenosine in the central nervous system. Annu. Rev.
Neurosci. 2001, 24, 31–55.
(10) Stiles, G. L. Adenosine receptors. J. Biol. Chem. 1992, 267, 6451–
6454.
(11) (a) Rosin, D. L.; Robeva, A.; Woodard, R. L.; Guyenet, P. G.;
Linden, J. Immunohistochemical localization of adenosine A2A
receptors in rat central nervous system. J. Comp. Neurol. 1998, 401,
163–186. (b) Fredholm, B. B.; Svenningsson, P. Striatal adenosine A2A
receptors-where are they? What do they do? Comments. Trends
Pharmacol. Sci. 1998, 19, 46–47.
(12) (a) Ishiwata, K.; Mishina, M.; Kimura, Y.; Oda, K.; Sasaki, T.;
Ishii, K. First visualization of adenosine A2A receptors in the
human brain by positron emission tomography with [11C]TMSX.
Synapse 2005, 55, 133–136. (b) Svenningsson, P.; Hall, H.; Sedvall, G.;
Fredholm, B. B. Distribution of adenosine receptors in the postmortem
human brain: an extended autoradiographic study. Synapse 1997, 27,
322–335.
(13) Pollack, A. E.; Fink, J. S. Adenosine antagonists potentiate D2
dopamine dependent activation of Fos in the striatopallidal path-
way. Neuroscience 1995, 68, 721–728.
(14) (a) Chen, J. F.; Xu, K.; Petzer, J. P.; Staal, R.; Xu, Y. H.; Beilstein,
M.; Sonsalla, P. K.; Castagnoli, K.; Castagnoli, N.; Schwarzchild,
M. A. Neuroprotection by caffeine and A2A adenosine receptor
inactivation in a model of Parkinson’s disease. J. Neurosci. 2001,
21, RC143/1–RC143/6. (b) Grondin, R.; Bedard, P. J.; Tahar, A. J.;
Gregoire, L.; Mori, A.; Kase, H. Antiparkinsonian effect of a new
adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurol-
ogy 1999, 52, 1673–1677. (c) Ongini, E.; Monopoli, A.; Impagnatiello,
F.; Fredduzzi, S.; Schwarzchild, M.; Chen, J. F. Dual actions of A2A
adenosine receptor antagonists on motor dysfunction and neurodegen-
erative processes. Drug Dev. Res. 2001, 52, 379–386. (d) Ikeda, K.;
Kurokawa, M.; Aoyama, S.; Kuwana, Y. Neuroprotection by adenosine
(25) (a) Bankiewicz, K. S. MPTP-induced parkinsonism in nonhuman
primates. Methods Neurosci. 1991, 7, 168–182. (b) Jakowec, M. W.;
Petzinger, G. M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-in-
duced lesion model of Parkinson's disease, with emphasis on mice
and nonhuman primates. Comp. Med. 2004, 54, 497–513. (c) Campos-
Romo, A.; Ojeda-Flores, R.; Moreno-Briseno, P.; Fernandez-Ruiz, J.
Quantitative evaluation of MPTP-treated nonhuman parkinsonian pri-
mates in the hallway task. J. Neurosci. Methods 2009, 177, 361–368.
(26) Kraus, G. A.; Sy, J. O. A synthetic approach to rocaglamide via
reductive cyclization of δ-keto nitriles. J. Org. Chem. 1989, 54, 77–83.